SIGN UP
LOG IN
MARKET
ABBV
ABBV
Abbvie Inc
NYSE
163.59
-1.07
-0.65%
Opening 09:36 04/19 EDT
OPEN
164.93
PREV CLOSE
164.66
HIGH
165.60
LOW
163.26
VOLUME
530.19K
TURNOVER
0
52 WEEK HIGH
182.89
52 WEEK LOW
125.85
MARKET CAP
289.66B
P/E (TTM)
60.17
1D
5D
1M
3M
1Y
5Y
Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth
Pfizer's share price has fallen about 10% since my last article on the company. The company's revenue grew 37.3% in the fourth quarter of 2023. Pfizer is one of the largest pharmaceutical companies in the world. I am upgrading Pfizer's rating from 'Buy' to 'Strong Buy' Key contributors to the company's free cash flow growth will be innovative drugs such as Abrysvo.
Seeking Alpha · 2h ago
Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S.
Alvotech, Teva signs deal to expand access for Humira biosimilar in U.S. Alvotech (ALVO) shares rose +3.03% to $13.28 premarket. The company signed a long-term agreement with a strategic partner to further enhance access to Humira.
Seeking Alpha · 2h ago
Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)
TipRanks · 3h ago
Market Correction Expected: 20 Stocks To Buy If It Worsens
Red flags for the stock market include insider selling, a 10Y treasury yield spike, and ongoing global tensions. The US consumer is strong, with the economy growing 3.4% in Q4. A market correction of 10% or more occurs every 1.2 years. I am expecting a correction of between 8% and 15%, presenting good opportunities to buy quality holdings.
Seeking Alpha · 3h ago
AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment
AbbVie's best-selling drug, Humira, lost its patent protection in Europe in 2020 and in the U.S. In 2023. The company will announce its Q1 2024 earnings pre-market next Friday. Wall Street is projecting revenues of $11.94bn and earnings per share of $2.28. ABBV share price has grown by over 110% in the past 5 years, but only 4% over the past 12 months.
Seeking Alpha · 19h ago
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
Cerevel Therapeutics Holdings Inc. Released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The trial met its primary endpoint. The drug is an adjunctive therapy to levodopa in adults.
Benzinga · 19h ago
Heard on the Street: AbbVie's Bet on a Neuroscience Drug Maker Just Got Better
AbbVie's Parkinsons disease drug performed well in a late-stage study. The drug is part of a new class of psychiatric drugs. Abbvie bought neuroscience biotech Cerevel Therapeutics in December for $8.7 billion. The Federal Trade Commission has been reviewing the deal.
The Wall Street Journal · 21h ago
AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition
AbbVie succeeds in late-stage trial for Rinvoq in inflammatory condition. Oral JAK inhibitor upadacitinib reached its main goals in a Phase 3 trial for giant cell arteritis. The company says the drug has the potential to be the first oral treatment for the condition.
Seeking Alpha · 1d ago
About ABBV
AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.
Webull offers AbbVie Inc stock information, including NYSE: ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.